Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | CDK9 | P50750 | 1/20 | 0.58 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.58 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11650361 | 0.83 | EPHX2 (0.61) | SMN1; SMN2EPHX2TP53EPHX1TSHR | |
| SCHEMBL10457010 | 0.83 | EPHX2 (0.61) | SMN1; SMN2EPHX2TP53EPHX1TSHR | |
| SCHEMBL5313666 | 0.79 | SMN1; SMN2 (0.56) | SMN1; SMN2EPHX2TP53EPHX1TSHR | |
| SCHEMBL5681693 | 0.79 | EPHX2 (0.56) | SMN1; SMN2EPHX2TP53EPHX1TSHR | |
| SCHEMBL28767340 | 0.79 | TP53 (0.56) | SMN1; SMN2EPHX2TP53EPHX1TSHR | |
| SCHEMBL8393640 | 0.79 | SMN1; SMN2 (0.56) | SMN1; SMN2EPHX2TP53EPHX1TSHR | |
| SCHEMBL9360689 | 0.79 | EPHX2 (0.56) | SMN1; SMN2EPHX2TP53EPHX1TSHR | |
| SCHEMBL8396654 | 0.79 | TP53 (0.56) | SMN1; SMN2EPHX2TP53EPHX1TSHR | |
| SCHEMBL897272 | 0.79 | HSD17B10 (0.58) | SMN1; SMN2EPHX2TP53EPHX1TSHR | |
| SCHEMBL3058572 | 0.79 | EPHX2 (0.56) | SMN1; SMN2EPHX2TP53EPHX1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288695-A1 | TSPAN2 AS SCAFFOLD PROTEIN FOR ENGINEERED EXTRACELLULAR VESICLES | EVOX THERAPEUTICS LIMITED (GB) | 2025-09-18 | — | — | US | disclosed |
| EP-4519427-A1 | TSPAN2 AS SCAFFOLD PROTEIN FOR ENGINEERED EXTRACELLULAR VESICLES | Evox Therapeutics Limited (GB) | 2025-03-12 | — | — | EP | disclosed |
| WO-2024137407-A1 | METHODS AND TARGETS OF DNA METHYLATION ENTROPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2023213979-A1 | TSPAN2 AS SCAFFOLD PROTEIN FOR ENGINEERED EXTRACELLULAR VESICLES | EVOX THERAPEUTICS LIMITED (GB) | 2023-11-09 | — | — | WO | disclosed |
| US-8222297-B2 | e.g. 1-[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]-3-{4-[bis(2-chloroethyl)amino]phenyl}urea; anticarcinogenic agent; improved chemical stability and efficacy; brain tumor, breast cancer, colon cancer, leukemia, and neuroblastoma | ACADEMIA SINICA (TW) | 2012-07-17 | — | — | US | disclosed |
| CN-1656073-B | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | NOVARTIS AG | 2010-05-26 | — | — | CN | disclosed |
| US-7652022-B2 | N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; | NOVARTIS AG (CH) | 2010-01-26 | — | — | US | disclosed |
| US-20080171765-A1 | Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2008-07-17 | — | — | US | disclosed |
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | FLOERSHEIMER ANDREAS | 2006-06-15 | — | — | US | disclosed |
| CN-1656073-A | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2005-08-17 | — | — | CN | disclosed |
| EP-0293839-A2 | Substituted phenyl (or pyridyl) urea compound and herbicidal composition containing the same as active ingredient | MITSUBISHI KASEI CORPORATION (JP) | 1988-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171765-A1 | Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | WEE1, PCNA, ATIC | SMN1; SMN2 4099/4885EPHX2 3730/4885TP53 6/4885 |
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | UCK2, PRKDC, PRKACA | SMN1; SMN2 2710/4885EPHX2 3155/4885TP53 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.